Is Pfizer Inc. (PFE) One of Goldman Sachs Top Healthcare Stocks?

Group 1 - Pfizer Inc. is recognized as one of Goldman Sachs' top healthcare stocks, with an Outperform rating and a price target of $30 set by BMO following positive phase 2 data on its tri-specific antibody tilrekimig [1][2] - The phase 2 trial results indicated that the once-a-month inhibitor achieved a placebo-adjusted efficacy of 51.9% in the middle-dose group, surpassing the 36% efficacy observed at 16 weeks for Regeneron's Dupixent [2][3] - These results suggest a potentially stronger competitive profile for Pfizer's investigational drug compared to existing treatments from Sanofi and Regeneron, enhancing Pfizer's position in the immunology and inflammation sectors [3] Group 2 - Pfizer is a leading global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing innovative medicines and vaccines, with a portfolio of over 150 products worldwide, including major COVID-19 vaccines and treatments [4]